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We evaluated the pharmacodynamic effects of the O
6-methylguanine-DNA methyltransferase (MGMT) inactivator lomeguatrib (LM)
on patients with melanoma in two clinical trials. Patients received temozolomide (TMZ) for 5 days either alone or with LM for 5, 10
or 14 days. Peripheral blood mononuclear cells (PBMCs) were isolated before treatment and during cycle 1. Where available, tumour
biopsies were obtained after the last drug dose in cycle 1. Samples were assayed for MGMT activity, total MGMT protein, and
O
6-methylguanine (O
6-meG) and N7-methylguanine levels in DNA. MGMT was completely inactivated in PBMC from patients
receiving LM, but detectable in those on TMZ alone. Tumours biopsied on the last day of treatment showed complete inactivation of
MGMT but there was recovery of activity in tumours sampled later. Significantly more O
6-meG was present in the PBMC DNA of
LM/TMZ patients than those on TMZ alone. LM/TMZ leads to greater MGMT inactivation, and higher levels of O
6-meG than TMZ
alone. Early recovery of MGMT activity in tumours suggested that more protracted dosing with LM is required. Extended dosing of
LM completely inactivated PBMC MGMT, and resulted in persistent levels of O
6-meG in PBMC DNA during treatment.
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Temozolomide (TMZ) is an oral methylating agent used in the
treatment of primary CNS tumours and melanoma. The drug
hydrolyses spontaneously to methyltriazenoimidazolecarboxamide.
This rapidly decomposes to a reactive methylating species that
attacks DNA to generate a number of adducts, the most common
being N7-methylguanine (N7-meG). Although constituting only 6%
of the total products, O
6-methylguanine (O
6-meG) is responsible for
the majority of the toxic effects of TMZ (Middleton and Margison,
2003). O
6-meG is a promutagenic, recombinogenic and cytotoxic
DNA lesion (Gerchman and Ludlum, 1973; Brennand and
Margison, 1986). These biological effects require two rounds of
DNA replication (Kaina et al, 1997) and a functional mismatch
repair (MMR) system is obligatory for cell killing (Karran and
Bignami, 1994).
The DNA repair protein O
6-methylguanine-DNA methyltrans-
ferase (MGMT) can remove the methyl group from O
6-meG in
DNA and hence can protect cells against the toxic effects of this
TMZ-induced damage (Middleton and Margison, 2003).
Many tumours express high levels of MGMT (Chen et al, 1992;
Citron et al, 1994) and dose-limiting toxicities occur in the bone
marrow, which expresses low levels of MGMT (Gerson et al, 1985).
The inactivation of MGMT might thus be expected to increase the
toxic effects of chemotherapy in tumours to a greater extent than
in the bone marrow, and hence improve the therapeutic index.
Combinations of methylating agents with nitrosoureas have
been used to attenuate MGMT activity. The methylating agent
generates O
6-meG in DNA and this consumes MGMT in being
repaired, rendering the cell susceptible to the nitrosourea (Lee
et al, 1993; Smith et al, 1996; Schold et al, 2000). Such
combinations proved to be unacceptably toxic in clinical trials
(Gerard et al, 1993; Clemons et al, 2003). The development of non-
toxic MGMT pseudosubstrates has enabled this strategy to be
revisited. O
6-meG itself was shown to be very inefficient (Gerson
et al, 1992) but its analogues, O
6-benzylguanine (Dolan et al, 1992)
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sand lomeguatrib (LM; 6-[4-bromo-2-thienyl]methoxypurin-2-
amine) (Middleton et al, 2000a; Ranson et al, 2006), are
considerably more potent MGMT inactivators and currently in
clinical trials.
We undertook a phase II trial of LM and TMZ (LM/TMZ) to
establish whether inactivation of MGMT by the former might
increase the efficacy of TMZ in patients with advanced melanoma.
The clinical outcome of the LM/TMZ combination was disappoint-
ing, with efficacy similar to that of standard dose TMZ (Ranson
et al, 2007). Here we present the detailed pharmacodynamic (PD)
analysis from that study, which used a 5-day LM/TMZ treatment
schedule, and show that there was post-LM/TMZ recovery of
tumour MGMT activity. We hypothesised that this would have
resulted in the repair of O
6-meG before the two rounds of DNA
replication required for cytotoxicity occurred. We have therefore
also assessed if extended dosing (10–14 days) with LM could
maintain MGMT inactivation. Although the intention was to assess
this in tumour material, only peripheral blood mononuclear cells
(PBMCs) were available from this study. We undertook to quantify
O
6-meG in PBMC DNA as a measure of the effect of MGMT
inactivation. Since the levels of the base would be affected by cell
turnover, we quantified the major DNA lesion 7-meG as a referent,
bearing in mind that this may be affected by the expression levels
of the DNA repair enzyme, 3-alkyladenine-DNA glycosylase
(AAG). The accompanying paper presents the clinical outcome
for the extended LM study.
PATIENTS AND METHODS
Patients
Patients with metastatic melanoma were eligible for the studies,
provided that they had not previously received systemic chemo-
therapy. The first trial was a multi-centre randomised study in
which 104 patients were allocated one of the two treatments: LM/
TMZ or TMZ alone. Patients experiencing disease progression on
TMZ alone were permitted to change to the LM/TMZ combination,
allowing assessment of whether LM could reverse resistance to
TMZ. The protracted LM study was based on the PD observations
described below and involved 34 patients, all treated with LM/
TMZ, of whom 10 contributed PD samples.
The studies were conducted in accordance with the International
Conference on Harmonisation of Good Clinical Practice guidelines
and the Declaration of Helsinki Principles. The trial was approved
by independent ethics committees according to national and local
requirements at each trial centre. All patients gave informed,
written consent.
Treatment
LM enteric-coated 10mg capsules were obtained from Kudos
Pharmaceuticals (Cambridge, UK), and TMZ was purchased from
Schering Plough Ltd (Welwyn Garden City, UK) as 5, 20, 100 and
250mg capsules.
Patients assigned LM/TMZ received LM 40mg per day p.o. for 5
consecutive days every 4 weeks for up to six cycles. Those among
the last 20 patients who were randomised to LM/TMZ received
LM 60 or 80mg per day. Temozolomide was administered at
125mgm
 2 per day p.o. 2h after LM. On the TMZ-alone arm,
patients received a starting dose of 200mgm
 2 per day,
administered on days 1–5 of a 4-week cycle. Patients receiving
LM/TMZ after progressing on TMZ alone were treated as above,
although the TMZ dose was adjusted to take into account any
earlier dose reductions on TMZ.
In the protracted LM study, patients received LM 40mg per day
p.o. twice daily for 10 or 14 consecutive days every 4 weeks for up
to six cycles. TMZ was administered at 75–125mgm
 2 per day
p.o. 2h after the first LM dose on days 1–5 of each cycle.
PBMC and tumour sampling
Peripheral blood mononuclear cell samples were obtained before
treatment, 6 and 24h after first LM dosing on day 1 and between 0
and 72h after last LM dose on day 5 of cycle 1. In the protracted
LM study, PBMC samples were obtained before and 4h after LM
dosing on day 1 and following last dose on day 10 or 14. Venous
blood (5–10ml) was collected into tubes containing 100ml 0.5 M
EDTA and stored on ice for up to 4h before isolation of PBMC.
Additional samples were drawn in patients in whom pharmaco-
kinetics (PK) were evaluated, these being 2, 4 and 8h after LM
administration on day 1 of cycle 1. Tumour biopsies were obtained
by excision biopsy between 0 and 72h after completion of the first
cycle of treatment. The biopsies were snap-frozen on dry ice and
stored at  801C.
A schematic diagram of the above treatment and sampling
schedules is shown in Figure 1.
MGMT activity
O
6-methylguanine-DNA methyltransferase activity in PBMC and
tumour cell sonicates was determined as previously described
(Watson and Margison, 2000).
Total MGMT protein
Total, that is, active and inactivated, MGMT protein was
determined in cleared tumour sonicates by ELISA. Briefly, 96-well
plates were coated with mouse anti-MGMT monoclonal antibody
(Abcam, Cambridge, UK) overnight at 41C. After washing with
PBS, blocking buffer (10% horse serum, 0.1% Tween 20 in PBS)
was added to each well and incubated for 2h at room temperature.
Blocking buffer was removed and the following 1h room tempera-
ture incubations were performed in sequence with washing
between additions: tumour sonicate, rabbit anti-MGMT polyclonal
antibody (Lee et al, 1996), goat anti-rabbit HRP antibody (Ely,
UK). Finally, plates were washed with PBS, Western Lightning
reagent (PerkinElmer, Beaconsfield, UK) was added and lumines-
cence was detected using a Tecan GENios plate reader.
O
6-ethylguanine-DNA methyltransferase values were extrapolated
from a purified human MGMT standard curve using Magellan v3
software.
N7-methylguanine
N7-methylguanine in DNA was quantified by an immunoslot blot
method and using the antibodies as previously described
Randomised study
TMZ (75–125 mg m–2)
Day
Sampling:
Day
PBMC
PBMC PBMC PBMC, tumour
PBMC
(cohorts 1 and 2)
PBMC
(cohort 3)
12345678
Sampling:
TMZ (125 mg m–2)
LM (40 mg)
Protracted study
LM (40–80 mg)
123456789 1 0 1 1 1 2 1 3 1 4
Figure 1 Schedules of treatment (above time lines) and sampling (below
time lines) for the randomised and protracted studies as indicated. Further
details are provided in the Patients and Methods section.
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s(Harrison et al, 2001) with one modification: instead of whole
tissue/cells, DNA was isolated from sonicates.
O
6-methylguanine
O
6-methylguanine in DNA was quantified using a modification of
the standard MGMT activity assay procedure (Watson and
Margison, 2000). Incrementally increasing amounts of the DNA
samples were pre-incubated with a standard amount of purified
recombinant human MGMT (Elder et al, 1994) and residual
activity was then determined. O
6-meG in DNA stoichiometrically
inactivates MGMT. Thus the amount of O
6-meG in the DNA
sample equals the amount of inactivation of the purified MGMT.
For the protracted LM study a more sensitive assay was used.
Briefly, the residual MGMT activity was determined by incubation
with a [
32P]-labelled oligonucleotide containing O
6-meG within a
PstI (New England Biolabs, Hitchin, Hertfordshire, UK) recogni-
tion site attached by 30biotin to the wells of streptavidin-coated
plates. Repair of the O
6-meG by the residual active MGMT results
in de-protection of the restriction site and, upon incubation with
PstI, release of a short radiolabelled oligonucleotide fragment into
the supernatant. Thus residual MGMT activity is proportional to
the amount of radioactivity present in the supernatant, quantified
in a TopCount machine (PerkinElmer).
RESULTS
The randomised study recruited 104 patients split equally into two
treatment arms. Of the 52 patients initially treated with TMZ alone,
27 were transferred to LM/TMZ at progression. Of the first 84
patients, those assigned to the LM/TMZ arm received 40mg per
day LM. The PD results obtained in the course of the study
indicated not quite complete MGMT inactivation and this forced
us to increase the daily LM dose.
Some samples were missed at the study site, deteriorated in
transit or were insufficient to perform all of the assays intended.
For the principal time points on the first day of treatment, data
were obtained from over 60% of the patients. Tumour biopsies
were taken in 25 instances: 14 from patients on LM/TMZ, 5 on
TMZ alone and 6 from patients on LM/TMZ having progressed on
TMZ alone.
Samples collected from 10 patients on protracted schedules of
LM were available for analysis. One patient was withdrawn on day
8; since the post-treatment sample was missing the other samples
collected from this patient were not analysed. In addition, not all
samples were sufficient to quantitate MGMT activity and DNA
methylation.
MGMT activity in PBMC
In PBMC, MGMT activity before treatment ranged between 2.3 and
51.6fmolmg
 1 DNA. The mean was similar for all the treatment
groups but was lower before starting LM/TMZ at progression
(Table 1). Levels fell more rapidly and completely with combina-
tion therapy than with TMZ alone. At 6 and 24h after LM dosing,
PBMC taken from patients on LM/TMZ had no detectable MGMT
activity. All TMZ-treated patients had residual activity, with
a mean of 88 and 74% of pre-treatment levels at 6 and 24h
respectively (Figure 2). Previous studies of MGMT in PBMC
Table 1 MGMT activity (fmolmg
 1 DNA) in extracts of PBMC samples from patients in the treatment groups indicated and as described in the Patients
and Methods section
Sampling time LM/TMZ, 40mg/day LM/TMZ, 60–80mg/day TMZ alone LM/TMZ on progression Protracted LM/TMZ
Pre-treatment
N 28 7 30 9 7
Mean 16.5 12.6 16.9 9.9 13.9
Range 2.30–48.3 7.40–18.3 4.7–51.6 3.7–15.7 7–15.5
2h
N 3— — 4—
Mean 6.43 — — 1.10 —
Range 0–15.7 — — 0–4.4 —
4h
N 2— — 3 6
Mean 0 — — 0 0.6
Range — — — 0–3.6
6h
N 27 6 27 7 —
Mean 0 0 14.4 0 —
Range — — 2.10–51.1 — —
8h
N 2— — 3—
Mean 0 — — 0 —
Range — — — — —
24h
N 26 3 26 4 —
Mean 0 0 12.5 0 —
Range — — 2.00–30.9 — —
End of treatment
N —— — — 4
Mean — — — — 0
Abbreviations: LM¼lomeguatrib; TMZ¼temozolomide.
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sfollowing TMZ alone showed progressive, but incomplete
inactivation (maximally B30% of activity remaining) over the
5-day schedule (Lee et al, 1994), broadly agreeing with
these observations. MGMT activity was undetectable in all samples
taken at the end of prolonged treatment (ie on day 10 or 14;
Table 1).
MGMT activity in tumour
Among the first 84 patients in the randomised trial, tumour
biopsies were obtained on days 6–8 of cycle one from 3 patients on
TMZ alone and from 9 on LM/TMZ (Table 2). Unexpectedly,
residual MGMT activity was detected in five of these nine samples.
The dose of LM given to subsequent patients was increased from
40 to 60mg and then 80mg to try to achieve complete tumour
MGMT inactivation. Despite this, residual activity was detectable
in six of seven tumour biopsies taken from LM/TMZ patients on
day 6 or 7. O
6-methylguanine-DNA methyltransferase was
completely inactivated in all four samples taken on day 5, within
hours of completing treatment (Table 2; Figure 3A). One of the two
samples obtained on day 5 of TMZ alone had residual MGMT
activity (Table 2).
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Figure 2 MGMT activity in PBMC sampled at the times indicated from patients treated with (A) TMZ alone and (B) LM/TMZ. Further details are
provided in the Patients and Methods section.
Table 2 MGMT activity (fmolmg
 1 DNA) in extracts of tumour samples
from patients in the treatment groups indicated and as described in the
Patients and Methods section
Sampling
time
LM/TMZ,
40mg/day
a
LM/TMZ,
60–80mg/day
a
TMZ
alone
Day 5
N —4 2
Mean — 0 1.38
Range — — 0–2.8
Day 6
N 66 2
Mean 0.64 2.79 1.23
Range 0–1.6 0–6.1 0–2.5
Day 7
N 21 1
Mean 0.4 5.6 0
Range 0–0.8 — —
Day 8
N 1— —
Value 4.5 — —
Abbreviations: LM¼lomeguatrib; TMZ¼temozolomide.
aTreated first line or after
progression on TMZ alone.
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Figure 3 (A) Active (filled columns) vs total (open columns) MGMT
protein in extracts of individual tumour biopsies taken from LM/TMZ
patients on days 5 (four samples), 6 (nine samples) and 7 (two samples) of
treatment cycle 1. Note that all samples were analysed for both parameters
and several of the samples had levels that were lower than the detection
limit. (B) O
6-MeG and (C) its ratio to N7-meG levels in DNA extracted
from PBMC taken at the end of treatment in cycle 1. Error bars represent
the s.e.m. for 9. TMZ, 13 LM/TMZ and 6 protracted LM/TMZ DNA
samples. Figure 1 contains a more comprehensive description of the
treatment and sampling schemes.
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sTotal MGMT protein
Total MGMT protein was determined in 15 tumour biopsies taken
following LM/TMZ (Figure 3A). O
6-methylguanine-DNA methyl-
transferase protein was detectable in all but two samples (both
taken on day 6). There was complete inactivation of MGMT in all
biopsies taken at cessation of treatment, on day 5. In the biopsies
taken on day 6 or 7 the amount of protein that was active ranged
from 0 to 73%. There was no correlation between the day of biopsy
and total MGMT protein levels.
DNA methylation damage
Mean pre-dose levels of N7-meG were below the lower limit
of quantitation (0.3fmolmg
 1 DNA) in 43 of the 49 PBMC DNA
samples isolated from previously untreated patients (Table 3).
N7-methylguanine was detectable in all five samples analysed
before LM/TMZ treatment from patients progressing on TMZ.
N7-methylguanine levels in PBMCs rose after treatment, with the
highest levels measured on day 6, the day after TMZ dosing was
completed. Patients treated with TMZ alone had the highest levels,
consistent with their daily dose of 200mgm
 2 as compared to the
75–125mgm
 2 administered within LM/TMZ. In patients treated
with protracted LM schedules, the mean N7-meG level for PBMC
samples taken at day 10 (16.1±2.6fmolmg
 1 DNA, n¼3) was
higher than that for those taken at day 14 (6.9±4.8fmolmg
 1
DNA, n¼4), consistent with the previous observation that levels
reduce over time. This is most likely due to cell turnover as a
consequence of toxicity and/or repair of N7-meG by AAG. Levels
of N7-meG in post-treatment tumour samples were consistent with
those observed in PBMC (Table 4).
Pre-dose levels of O
6-meG were less than the lower limit of
quantitation (0.5fmolmg
 1 DNA) in all PBMC DNA samples
analysed (Table 5). Mean O
6-meG levels in DNA from post-
treatment PBMC samples were lower with TMZ alone than
with LM/TM (Table 5; Figure 3B; Pp0.05). The ratio of O
6-meG
to N7-meG in the same sample was twice as high on LM/TMZ as
with TMZ alone (Figure 3C; P¼0.0005). Where longer courses of
LM were given, mean O
6-meG levels in DNA from PBMC samples
were higher at day 10 than at day 14 (Table 5). Since levels of N7-
meG were also reduced and MGMT activity was not detectable, this
is probably due to cell turnover, that is, dilution of O
6-meG in
DNA by routine replacement of PBMC in the blood.
DISCUSSION
We have previously reported that the clinical activity of LM/TMZ
was similar to that of TMZ alone, and that no patients progressing
Table 3 Levels of N7-meG (fmolmg
 1 DNA) in DNA extracted from
PBMC samples from patients in the treatment groups indicated and as
described in the Patients and Methods section
Sampling
time LM/TMZ
TMZ
alone
LM/TMZ at
progression
Protracted
LM/TMZ
Pre-dose
N 22 20 5 7
Mean 0.02 0.19 3.56 0.33
Range 0–0.5 0–3.0 1.5–6.1 0–0.5
Day 5
N 15 1 —
Mean 38.0 52.9 51.0 —
Range — 41.6–80.1 — —
Day 6
N 12 8 1 —
Mean 43.7 55.9 49.4 —
Range 29.7–64.2 34.1–79.3 — —
Day 7
N 10 5 3 —
Mean 35.9 43.6 35.3 —
Range 18.4–55.5 34.7–52.6 20.9–51.3 —
Day 8
N 34 1 —
Mean 24.3 42.8 34.4 —
Range 17.7–29.2 28.3–64.7 — —
Day 10
N —— — 3
Mean — — — 16.1
Range — — — 13.1–18.0
Day 14
N —— — 4
Mean — — — 6.9
Range — — — 3.6–13.9
Abbreviations: LM¼lomeguatrib; TMZ¼temozolomide.
Table 4 Levels of N7-meG (fmolmg
 1 DNA) in DNA extracted from
tumour samples from patients in the treatment groups indicated and as
described in the Patients and Methods section
Sampling time LM/TMZ TMZ alone LM/TMZ on progression
Day 6
N 41 2
Mean 36.0 40.1 50.6
Range 27.8–49.6 — 47.9–53.2
Day 7
N 11 1
Value 38.8 40.4 33.3
Day 8
N 1— —
Value 25.6 — —
Abbreviations: LM¼lomeguatrib; TMZ¼temozolomide.
Table 5 Levels of O
6-meG (fmolmg
 1 DNA) in DNA extracted from
PBMC samples from patients in the treatment groups indicated and as
described in the Patients and Methods section
Sampling time LM/TMZ TMZ Alone Protracted LM/TMZ
Pre-dose
N —— 4
Mean — — 0
Day 5–8
N 13 9 —
Mean 6.1 3.9 —
Range 2.3–10.9 1.3–7.1 —
Day 10
N —— 4
Mean — — 3.3
Range — — 2.2–5.4
Day 14
N —— 4
Mean — — 1.4
Range — — 0.9–2.2
Abbreviations: LM¼lomeguatrib; TMZ¼temozolomide.
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son the latter subsequently responded to LM/TMZ (Ranson et al,
2006). Here we present the PD findings of this study, together with
the subsequent protracted LM dose study. Levels of MGMT activity
in PBMC were comparable with those previously reported (Ranson
et al, 2006, 2007). There was slow and incomplete inactivation
following treatment with TMZ and more rapid, total, depletion
with LM/TMZ, consistent with our previous trial (Ranson et al,
2006).
N7-methylguanine was detectable, albeit at very low levels, in
12% of the pre-treatment PBMCs, consistent with previous
measurements in the blood of non-smokers (Harrison et al,
2001). This may reflect exposure of these individuals to environ-
mental or endogenous methylating agents and/or deficiency in
AAG. Post-treatment levels were highest in the patients treated
with TMZ alone, due to the higher dose of TMZ given. Importantly,
N7-meG levels per unit dose were similar, consistent with the
observation that LM had no effect on the PK of TMZ in those
patients on LM/TMZ. We found increased levels of N7-meG in all
of the TMZ progressors before they started on LM/TMZ: these
patients had already undergone at least two treatment cycles with
TMZ and the relatively slow repair of N7-meG is well documented
(Lawley et al, 1986).
Despite the much lower dose of TMZ administered in
combination with LM, the levels of O
6-meG were significantly
greater in the PBMC of patients on combination therapy. Thus the
ratio of O
6/N7-meG was significantly higher in these patients than
those on TMZ alone, confirming that effective and prolonged
inactivation of MGMT, as was the case in PBMC, results in
increased levels of the potentially toxic lesion O
6-meG in DNA.
These increased levels of O
6-meG in PBMC are likely to reflect
increasing levels in blood progenitor cells and hence the increased
haematological toxicity in patients receiving LM/TMZ. Unfortu-
nately, we were unable to compare levels of O
6-meG in tumour
DNA between the treatment groups due to the low amounts of
tumour DNA available and the sensitivity of the assay.
In the phase 1 study of LM/TMZ, we observed complete
inactivation of tumour MGMT after a single dose of LM in three of
five patients with melanoma and 496% inactivation in the other
two. In that trial, tumours were biopsied before and 4h after the
first LM dose. In the current study, to avoid the possibility of
inherent differences between two tumour biopsies (as observed in
earlier studies, Egyha ´zi et al, 1997) we measured total (active and
inactive) MGMT using an ELISA assay and active MGMT using our
functional activity assay. None of the four tumours sampled on day
5 of LM/TMZ treatment had residual MGMT activity, although
ELISA showed that MGMT protein was present in all cases.
However, we found residual MGMT activity in the majority of
tumour biopsies taken at later times after the end of the first LM/
TMZ cycle, even when the daily dose of LM was increased.
It appears therefore that MGMT activity can recover rapidly
after LM/TMZ treatment. This finding is significant, in that
O
6-meG is toxic only after two rounds of DNA replication, so that
MGMT-mediated repair occurring before this (Kaina et al, 1997)
or even after one round of DNA replication (Lips and Kaina 2001)
will diminish cytotoxicity. Recovery of MGMT activity after dosing
may not mean that complete repair of O
6-meG has taken place,
at least not across the whole tumour. We have found MGMT
activity along with its substrate DNA lesion, O
6-meG, in the same
melanoma biopsy in a previous trial (Middleton et al, 2000b). This
observation could reflect ongoing synthesis and inactivation in all
cells, or adducts persisting in the fraction of cells in which MGMT
recovery has not begun.
The critical factor for toxicity is whether recovery of MGMT
activity takes place before DNA replication across a template
containing O
6-meG. One report, based on a study of 83 primary
and metastatic malignant melanomas, indicates a potential
doubling time (Tpot) of human melanoma of 7.2 days (range
3.5–41 days) (Rew and Wilson, 2000). Human A375M melanoma
cells and many of the other tumour cell lines studied in culture
divide about every 24h. The low cell-doubling rate in patients’
tumours and the observed rapid recovery of MGMT activity
suggest repair of O
6-MeG may well precede two rounds of DNA
replication, in contrast to the situation in cell culture and tumour
xenograft models. It also contrasts with the reported doubling time
of 24h for the transit cell population of human bone marrow (Rew
and Wilson, 2000; Begg, 2002), a factor that probably explains the
increased haematological toxicity of combination therapy.
To test whether more protracted MGMT inactivation would
enhance the effectiveness of TMZ, we conducted a study to
examine the effect of an LM/TMZ combination with extended LM
dosing to 10 or 14 days. The clinical outcome, reported in detail in
the accompanying paper, showed no benefit, despite the continued
suppression of MGMT activity and consequent persistence of
O
6-meG, at least in PBMC and PBMC DNA. The increased
haematological toxicity is indicative of the importance of
O
6-meG, and it is reasonable to speculate that factors downstream
of O
6-meG, such as MMR and anti-apoptotic factors, and/or other
TMZ-induced DNA lesions may have decisive functions in the
resistance of melanoma to TMZ. In addition, with respect to
DNA repair processes, recent studies show that a wide range of
such processes are upregulated in poor prognosis melanoma
(Kauffmann et al, 2008). More specifically, the effects of targeting
the base excision repair pathway by blocking the processing of
apurinic sites (Yan et al, 2007) or single-strand breaks through
inhibition of poly-ADP-ribose polymerase activity (Naumann et al,
2009) are currently being assessed in clinical trials. Improving
response rates in melanoma may rest on modulating these and
other factors, in combination with the suppression of MGMT
activity.
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